.jpg "Esther De La Cuesta, MD, MBA photo")
Senior Director, Clinical Development
Bayer HealthCare Pharmaceuticals, Inc.
Dr. Esther De La Cuesta has extensive experience in the Pharmaceutical Industry that spans 26 years across multiple therapeutic areas including Oncology, Cardiovascular and Immunology. She has experiences in drug development through all development phases, Medical Affairs, Business Development and Pharmacovigilance to support submissions, product launches and post marketing safety activities.
She has held positions of increasing responsibility and of strategic importance at Rhone Poulenc Rorer (Aventis), Bristol Myers Squibb, Abbott (AbbVie), Vertex andTakeda where she led the strategic geographical expansions for established products to emerging markets before joining Bayer in 2017 as Therapeutic Area Head – Oncology (TKIs/ADCs/Loxo) in Benefit Risk Management. After many years in PV, she decided to join the Bayer Research and Development Oncology as Senior Clinical development Leader and leads the pediatric program (SCOUT) for Larotrectinib. She was a key contributor to 2 successful NDAs (ODAC) and 1 EMDAC; and has global experience with effective communications/interactions with multiple Regulatory Authorities e.g., FDA, EMA, HC, MHRA, PMDA and BfArM.
Dr. De La Cuesta obtained her MD from the University of St. Thomas in the Philippines and has a Master’s Degree in Business Administration (MBA), Healthcare from Penn State University.
